BASIN ST BLUES NWBO is institutionally BLIGHTED, ignored for the most part because/b]:
1. The two comparable public co's BLEW IT:
FOREMOST is DNDN's COLOSSAL FAILURE As the ONLY FDA immunotherapy cancer RX approved for Prostate Cancer (PC) AND the company really screwed up in terms of difficulty of application; has to be done by a special facility requiring trained personnel.More importantly they could not scale up mfg hence their pdtn costs went thru the roof. Also the FDA made them do another clinical that resulted in more delays. As this was happening both JNJ and MDVN got their PC drugs approved and since their pdt costs were lower did NOT run into serious reimbursement issues like DNDN. Many physicians went to JNJ & MDVN PC drugs because they cost less and those are pills vs that of DNDN. To add further insult to injury the CEO Mitch Gold WAY OVERFORECASTED demand and UNDERESTIMATED mfg costs (THE KEY)and PILED on DEBT. THREE STRIKES HERE. When he finally realized that all these key variables and the fact that JNJ & MDVN were beating him he finally did a MAJOR REVERSAL: TWO LARGE SCALE CUTBACKS! He resigned.THAT WAS ONLY TWO YEARS AGO so still fresh in Institutional Mindset IMHO And the CEO who followed him is LEAVING. When the stock was $5 not to long ago, I literally said to myself: it's going chapt 11 because who would want to buy it!The whole DNDN extreme roller coaster and MGT royally screwing up is the most PROMINENT reason why NWBO has low instl ownership
IMUC reported very disappointing PH2 results last Dec '13 and shares got slammed
.Institutions look just superficially on the surface of NWBO without clearly understanding the draconian differences that I underscored in some of my earlier posts: the LP interview describing the strategic differences of how NWBO does it vs DNDN 1)
Here's the post containing CEO Linda Powers views (4 yrs ago but still RELEVANT! of why NWBO is so vastly different than DNDN which institutions likely have not read or shelved till a DEFINITIVE announcement takes place:
maverick_1 Member Level Saturday, 07/12/14 11:18:54 AM
Re: longusa post# 15464
Post # of 16543
Elaboration on DNDN strategic flaws from CEO!
Much thanks LongUSA for yet another elucidation to ramify and reinforce/add to LP's interview.
IMHO time for a much needed refresher course.
Copied and pasted below in it's entirety:"straight from the horse's mouth" BioMedReports Interview:
maverick_1 Member Level Saturday, 07/12/14 11:18:54 AM
Re: longusa post# 15464
Post # of 16543
Elaboration on DNDN strategic flaws from CEO!
Much thanks LongUSA for yet another elucidation to ramify and reinforce/add to LP's interview.
IMHO time for a much needed refresher course.
Copied and pasted below in it's entirety:"straight from the horse's mouth" BioMedReports Interview:
WORTHY OF A BOOKMARK; STICKY as it is WHY NWBO HAS SUPERIOR TECHNOLOGY as well as a fraction of the cost vs that of clearly dethroned and nearing extinction (DNDN's Provenge):
Cancer Vaccines: Northwest Biotherapeutics -vs- Dendreon
By M.E.Garza
Thursday, 15 July 2010 04:59
1
As a follow up to our interview with Northwest Biotherapeutics’ (NWBO.OB) Chairman of the Board of Linda Powers, this article focuses on the “hard differentiators” between NWBO’s immunotherapy vaccine platform and that of their closest competitor Dendreon Corporation (Nasdaq: DNDN).
Observers and investors of Northwest Biotherapeutics now believe the company’s DCVax® may be poised to surpass Dendreon’s product in the field of vaccine based cancer treatments. Speculators have begun to rush back to pick up shares of NWBO just as sector darling Dendreon Corp. (NASDAQ: DNDN) has lost 44% of its value after news that Dendreon can only make enough of their recently approved prostate cancer drug to treat about 2% of eligible patients.
First factor: The quality and characteristics of the antigens used by both companies in their vaccines
Dendreon uses PAP, while NWBO uses PSMA. Terminology aside, what matters here according to representatives at NWBO is Dendreon’s target antigen is not expressed on all prostrate cancers. They have to screen their patients to see the expression of their target. NWBO’s target antigen is expressed on all prostrate cancers. Additionally, with Dendreon’s target, the level of expression goes down as the cancer progresses. The level of expression on NWBO’s target goes up as the cancer progresses. As we learned from NWBO’s Chairman Linda Powers, if your target is getting harder and harder for the vaccine to find and hit as the cancer progresses, that’s not the characteristic you want in your target antigen.
Another difference in the target antigens is NWBO’s target is bound to the membrane of the tumor cell. “If the DCVax® hits our target,” explains Linda Powers, “it hits the cell for sure. Dendreon’s target is secreted by the cell, so while the target is close by, it is not necessarily bound to the cell in every instance. Antibodies can come along and glom onto to the target and not hit the cell itself, which means accuracy is an issue.
Second factor: The manufacturing and purity of the product
The active ingredient in both companies’ vaccines is dendritic cells. That is an active pharmaceutical ingredient, it’s the active agent that’s doing the job. But according to data provided by Northwest Biotherapeutics, the percentage composition of Dendreon’s product by the company’s own published material is 15% antigen presenting cells -- dendritic cells and others. According to NWBO’s published material, DCVax® is over 80% active ingredient. The official product release criteria are over 80% and Northwest Biotherapeutics’ platform usually hits over 90%, thus the active ingredient in NWBO’s vaccine is much more concentrated.
Third factor: How is the product administered to the patient
According to Powers, because there is such a low percentage of active ingredient in Dendreon’s vaccine, they have to deliver a huge volume, and the only way to do it is intravenous infusion, which is how they deliver Provenge to their patients.
This IV delivery can take over an hour. By contrast, because the active ingredient is so concentrated in the DCVax® vaccine, NWBO only needs to administer a tiny volume of “just a few drops” and it’s administered with a simple injection under the skin, like a flu shot or insulin shot.
As is the case with most medications, where and how a vaccine is administered has a big effect on how well the vaccine can do its job once it’s put into patient’s body. The human body has a blood circulatory system and a lymph circulatory system which is separate and parallel. Dendritic cells do their job in the lymph system, in the lymph nodes.
UNLESS mgt has previously demonstrated a successful record of succeeded in securing FDA approval and operating profitably with
expected revenues, or that mgt has sold a successful enterprise, biotech mgrs require at the very least some clear but DEFINITIVE
INDICATIONs (ie L Efficacy; GBM reimb.terms/revs from Germany) before taking on a position of an unknown like NWBO.
They don't need to be a hero as there is a lot of fish to fry in the biotech space.
THE ABOVE IS JUST ON THE FUNDAMENTAL SIDE
WHEN institutions have the above in place meaning some or all ofthe DEFINITIVE indications Announcement then...
How can I get SIZE w/o affecting price(typically only at a secondary)as they would normally like to avoid the open market since the float is thin.
If you'd like to sell suggest you contact Les Goldman who may set you up with a buyer: that would be good for EVERYONE IMHO!
GL Basin Stret Blues
PM me if needed.
AI
